Klem Fabiane, Wadhwa Akhilesh, Prokop Larry J, Sundt Wendy J, Farrugia Gianrico, Camilleri Michael, Singh Siddharth, Grover Madhusudan
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; Universidade Federal do Paraná, Curitiba, Paraná, Brazil.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Gastroenterology. 2017 Apr;152(5):1042-1054.e1. doi: 10.1053/j.gastro.2016.12.039. Epub 2017 Jan 6.
BACKGROUND & AIMS: Foodborne illness affects 15% of the US population each year, and is a risk factor for irritable bowel syndrome (IBS). We evaluated risk of, risk factors for, and outcomes of IBS after infectious enteritis.
We performed a systematic review of electronic databases from 1994 through August 31, 2015 to identify cohort studies of the prevalence of IBS 3 months or more after infectious enteritis. We used random-effects meta-analysis to calculate the summary point prevalence of IBS after infectious enteritis, as well as relative risk (compared with individuals without infectious enteritis) and host- and enteritis-related risk factors.
We identified 45 studies, comprising 21,421 individuals with enteritis, followed for 3 months to 10 years for development of IBS. The pooled prevalence of IBS at 12 months after infectious enteritis was 10.1% (95% confidence interval [CI], 7.2-14.1) and at more than 12 months after infectious enteritis was 14.5% (95% CI, 7.7-25.5). Risk of IBS was 4.2-fold higher in patients who had infectious enteritis in the past 12 months than in those who had not (95% CI, 3.1-5.7); risk of IBS was 2.3-fold higher in individuals who had infectious enteritis more than 12 months ago than in individuals who had not (95% CI, 1.8-3.0). Of patients with enteritis caused by protozoa or parasites, 41.9% developed IBS, and of patients with enteritis caused by bacterial infection, 13.8% developed IBS. Risk of IBS was significantly increased in women (odds ratio [OR], 2.2; 95% CI, 1.6-3.1) and individuals with antibiotic exposure (OR, 1.7; 95% CI, 1.2-2.4), anxiety (OR, 2; 95% CI, 1.3-2.9), depression (OR, 1.5; 95% CI, 1.2-1.9), somatization (OR, 4.1; 95% CI, 2.7-6.0), neuroticism (OR, 3.3; 95% CI, 1.6-6.5), and clinical indicators of enteritis severity. There was a considerable level of heterogeneity among studies.
In a systematic review and meta-analysis, we found >10% of patients with infectious enteritis develop IBS later; risk of IBS was 4-fold higher than in individuals who did not have infectious enteritis, although there was heterogeneity among studies analyzed. Women-particularly those with severe enteritis-are at increased risk for developing IBS, as are individuals with psychological distress and users of antibiotics during the enteritis.
食源性疾病每年影响15%的美国人口,是肠易激综合征(IBS)的一个风险因素。我们评估了感染性肠炎后IBS的风险、风险因素及后果。
我们对1994年至2015年8月31日的电子数据库进行了系统评价,以确定关于感染性肠炎3个月或更长时间后IBS患病率的队列研究。我们使用随机效应荟萃分析来计算感染性肠炎后IBS的汇总点患病率,以及相对风险(与无感染性肠炎的个体相比)和宿主及肠炎相关的风险因素。
我们确定了45项研究,包括21421例肠炎患者,随访3个月至10年以观察IBS的发生情况。感染性肠炎后12个月时IBS的合并患病率为10.1%(95%置信区间[CI],7.2 - 14.1),感染性肠炎后超过12个月时为14.5%(95%CI,7.7 - 25.5)。过去12个月内患有感染性肠炎的患者发生IBS的风险比未患感染性肠炎者高4.2倍(95%CI,3.1 - 5.7);12个月前以上患有感染性肠炎的个体发生IBS的风险比未患感染性肠炎者高2.3倍(95%CI,)。由原生动物或寄生虫引起肠炎的患者中,41.9%发生了IBS,由细菌感染引起肠炎的患者中,13.8%发生了IBS。女性(优势比[OR],2.2;95%CI,1.6 - 3.1)、有抗生素暴露史者(OR,1.7;95%CI,1.2 - 2.4)、焦虑者(OR,2;95%CI,1.3 - 2.9)、抑郁者(OR,1.5;95%CI,1.2 - 1.9)、躯体化者(OR,4.1;95%CI,2.7 - 6.)、神经质者(OR,3.3;95%CI,1.6 - 6.5)以及肠炎严重程度的临床指标者发生IBS的风险显著增加。各研究之间存在相当程度的异质性。
在一项系统评价和荟萃分析中,我们发现超过10%的感染性肠炎患者后来发生了IBS;IBS的风险比未患感染性肠炎者高4倍,尽管在分析的研究之间存在异质性。女性——尤其是肠炎严重者——发生IBS的风险增加,肠炎期间有心理困扰者和使用抗生素者也一样。